Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Bilateral Comparison, Vehicle-Controlled, Safety and Tolerability Study of Topical PAT-001 for the Treatment of Congenital Ichthyosis

Next Previous
X
Search
Trial Profile

A Randomized, Bilateral Comparison, Vehicle-Controlled, Safety and Tolerability Study of Topical PAT-001 for the Treatment of Congenital Ichthyosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isotretinoin (Primary)
  • Indications Congenital ichthyosiform erythroderma
  • Focus Adverse reactions; Proof of concept
  • Sponsors Patagonia Pharmaceuticals

    • Most Recent Events

    • 15 Feb 2024 According to Timber Pharmaceuticals media release, Timber Pharmaceuticals has changed its name to Trex Wind-down
    • 07 Mar 2022 Results published in the Journal of the American Academy of Dermatology
    • 01 Oct 2021 According to a Timber Pharmaceuticals media release, results from this trial will be presented at the European Academy of Dermatology and Venereology's (EADV) 30th anniversary congress, 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top